These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31691081)

  • 1. M0CRPC overview of management options.
    Hess-Busch Y; Hadaschik B; Hess J
    World J Urol; 2021 Feb; 39(2):349-356. PubMed ID: 31691081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.
    Swami U; Agarwal N
    Cancer Treat Res Commun; 2020; 25():100205. PubMed ID: 32822968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and trials in non-metastatic castration-resistant prostate cancer.
    Lokeshwar SD; Klaassen Z; Saad F
    Nat Rev Urol; 2021 Jul; 18(7):433-442. PubMed ID: 34002069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
    Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
    Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies.
    Alpajaro SIR; Harris JAK; Evans CP
    Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):16-23. PubMed ID: 30115959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
    Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
    Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
    J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
    Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Wenzel M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Tilki D; Graefen M; Kluth LA; Briganti A; Mandel P; Montorsi F; Chun FKH; Karakiewicz PI
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):139-148. PubMed ID: 34054128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-metastatic castration-resistant prostate cancer (M0CRPC) - Apalutamide in high-risk M0CRPC: case reports from the SPARTAN study and the apalutamide compassionate use program].
    Spiegelhalder P; Bögemann M
    Aktuelle Urol; 2022 Feb; 53(1):60-63. PubMed ID: 33882583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
    George DJ; Morgans AK; Constantinovici N; Khan N; Khan J; Chen G; Hlebec V; Shore ND
    JAMA Netw Open; 2024 Aug; 7(8):e2429783. PubMed ID: 39190308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.
    Appukkuttan S; Farej R; Miles L; Purser M; Wen L
    J Manag Care Spec Pharm; 2021 Feb; 27(2):166-174. PubMed ID: 33141615
    [No Abstract]   [Full Text] [Related]  

  • 14. A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents.
    Rizzo A; Oderda M; Mollica V; Merler S; Morelli F; Fragomeno B; Taveri E; Sorgentoni G; Santoni M; Massari F
    Anticancer Drugs; 2022 Jan; 33(1):e43-e51. PubMed ID: 34387593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Tombal B; Sternberg CN; Hussain M; Ganguli A; Li Y; Sandin R; Bhadauria H; Oh M; Saad F
    ESMO Open; 2022 Jun; 7(3):100510. PubMed ID: 35714477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison.
    Shore N; Jiang S; Garcia-Horton V; Terasawa E; Steffen D; Chin A; Ayyagari R; Partridge J; Waldeck AR
    Adv Ther; 2022 Nov; 39(11):5025-5042. PubMed ID: 36028656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Dearden L; Capone C; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2022 Jan; 39(1):518-531. PubMed ID: 34797506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer.
    Wang SS; Bian XJ; Wu JL; Wang BH; Zhang S; Ye DW
    Asian J Androl; 2024 Jul; 26(4):402-408. PubMed ID: 38624195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis.
    Roumiguié M; Paoletti X; Neuzillet Y; Mathieu R; Vincendeau S; Kleinclauss F; Mejean A; Guy L; Timsit MO; Lebret T
    Future Oncol; 2021 May; 17(14):1811-1823. PubMed ID: 33543650
    [No Abstract]   [Full Text] [Related]  

  • 20. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Lefebvre P; McQuarrie K; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2020 Jan; 37(1):512-526. PubMed ID: 31813087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.